Abametapir is a pediculicide metalloproteinase used topically in the treatment of head lice infection. The life cycle of head lice (Pediculus capitis) is approximately 30 days, seven to twelve of which are spent as eggs laid on hair shafts near the scalp.
- Mechanism
- Curator reviewed · 6 references
There are several metalloproteinases (enzymes requiring metal co-factors to function) involved in the process of louse egg hatching and survival. In vitro studies have demonstrated that metal-chelating agents can inhibit the activity of these proteins, and may therefore be valuable pediculicidal agents.
Abametapir is a metalloproteinase inhibitor that targets louse metalloproteinases which are critical to their development and hatching.
- Primary indication
- Abametapir is indicated, in the context of an overall lice management program, for the topical treatment of head lice infestation in patients 6 months of age and older.Curator reviewed · 1 structured indication
- Formula / weight
- C12H12N2 · 184.242 g/mol (avg)
- First approval
- United States, 2021
- Code names
- BRN 0123183 · HA-44
- Brand names
Resolves to
PTRATZCAGVBFIQ-UHFFFAOYSA-NSMILESCC1=CC=C(N=C1)C1=CC=C(C)C=N1What you can answer from here — as of September 19, 2026
Which drugs share a target with Abametapir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account